Table 1 Inhaled formulations marketed or undergoing clinical studies for pulmonary infectious disease treatment
From: A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases
Disease | Formulation | Therapeutics (brand/registered name) | Development statusa | |
|---|---|---|---|---|
Bacterial infection with CF | Inhalation solution | Tobramycin (Tobi®, Bramitob®) | Marketed | |
Dornase alfa (Pulmozyme®) | Marketed | |||
Levofloxacin (Aeroquin® (formerly MP-376)) | Phase III (NCT01270347, NCT01180634) | |||
Lyophilized powder for inhalation solution | Aztreonam lysine (Cayston®) | Marketed | ||
Colistimethate sodium (Promixin®) | Marketed | |||
Inhalable lipid particles (Pulmosphere™) | Tobramycin (Tobi® Podhaler™) | Marketed | ||
Inhalable dry powder | Ciprofloxacin (Cipro Inhale (BAYQ3939)) | Phase III (NCT01764841) | ||
Excipient-free spray-dried powders | Colistimethate sodium (Colobreathe®) | Marketed | ||
Mannitol (Bronchitol®) | Marketed | |||
Pulmonary TB | Aerosol | Inhalation solution | Ad5Ag85A | Phase I (NCT02337270) |
Dry powder | Inhalable dry powder | Amikacin | Phase I (NCT04249531) | |
Mycobacterium avium complex lung disease | Aerosol | Liposomes for nebulization | Amikacin (ARIKAYCE Kit) | Marketed |
| Â | Dry powder | Dry powder inhaler | Budesonide (PULMICORT) | Phase II (NCT04416399) |
Nanoparticle powder for inhalation | Remdesivir (GS-5734â„¢) (VEKLURY) | Phase I (NCT04480333) | ||
Excipient-free dry powder | Ivermectin | Phase III (NCT04681053) | ||
Dry powder for nebulization | Melphalan | Phase II (NCT04380376) | ||
TD-0903 | JAK inhibitor | Phase I (NCT04350736) | ||
Dry powder for nebulization | A synthetic version of Vasoactive Intestinal Polypeptide (ZYESAMIâ„¢ (aviptadil acetate)) | Phase II/III (NCT04360096) | ||
SNG001 | Interferon beta 1a | Phase II (NCT04385095) Phase III (NCT04732949) | ||
AP-003 | Interferon alpha 2b | Phase I/II (NCT04988217) | ||
Dry powder inhaler | Sargramostim (Leukine®) | Phase II/III (NCT04642950) | ||
Aerosol | SPRAY | Ciclesonide (OMNARIS) | Phase II (NCT04381364, NCT04330586) | |
HCQ01 | Hydroxychloroquine sulfate | Phase I/II (NCT04731051) | ||
S-1226 (8%) | Carbon dioxide (8%) and perflubron (PFOB) | Phase II (NCT04949386) | ||
Inhalation Solution | ILOPROST (VENTAVIS) | Phase II (NCT04445246) | ||
Nebulizer inhalation solution | Saline containing 0.3% hyaluronic acid sodium salt (Yabro®) | Phase II (NCT04830020) | ||
Nasal spray | Ivermectin | Phase II (NCT04510233) | ||
Nasal spray | Sodium Pyruvate | Phase II/III (NCT04824365) | ||
Inhalation solution | Adenosine | Phase II (NCT04588441) | ||
Inhalation solution | 13-cis retinoic acid | Phase II (NCT04396067) | ||
Inhalation solution | Virazole (Virazole®) | Phase I (NCT04551768) | ||
Inhalation solution | Nitric oxide (RESP301) | Phase II (NCT04858451) | ||
Inhalation solution | Furosemide | Phase II/III (NCT04588792) | ||
Nebulized inhalation solution | Captopril | Phase II (NCT04355429) | ||
Inhalation solution | synthetic form of Human Vasoactive Intestinal Polypeptide (Aviptadil) | Phase II (NCT04536350) | ||
Nebulized inhalation solution | Alpha 1-Antitrypsin (GlASSIA) | Phase I (NCT04385836) | ||
Nebulized inhalation solution | Interferon beta 1b (EXTAVIA) | Phase II (NCT04469491) | ||
Nebulizer inhalation solution | GM-CSF (rHuGM-CSF) (Molgramostim) | Phase II (NCT04569877) | ||
Nebulized inhalation solution | Sargramostim (GM-CSF) (Leukine®) | Phase II (NCT04707664) | ||
BI 767551 | Antibody against the coronavirus SARS-CoV-2 | Phase II/III (NCT0489447, NCT04822701) | ||
DZIF-10c | SARS-CoV-2-neutralizing monoclonal antibody | Phase I/II (NCT04631705) | ||
DAS181 | Recombinant Sialidase Protein | Phase II/III (NCT04354389) | ||
Inhalation Solution | Dornase Alfa (PULMOZYME) | Phase III (NCT04402970) | ||
Inhalation solution | The low molecular weight filtrate of human serum albumin (Ampion) | Phase II (NCT04868890) | ||
Inhalation solution | A novel recombinant antiviral protein (Novaferon) | Phase III (NCT04669015) | ||
Powder for inhalation solution | Recombinant tissue-Plasminogen Activator (rt-PA) | Phase II (NCT04356833) | ||
Nebulizer inhalation solution | Ad5-nCoVÂ (Recombinant Novel Coronavirus Vaccine) | Phase I (NCT04552366) Phase I/II (NCT04840992) | ||
Natural nano-sized vesicles for inhalation | EXO1 EXO2 | Phase II (NCT04491240, NCT04602442) | ||
Overexpressing CD24 nano-sized vesicles for inhalation | EXO-CD24 | Phase I (NCT04747574) | ||
COVID-19 specific T cell derived nano-sized vesicles for inhalation | CSTC-Exo | Phase I (NCT04389385) | ||
Nano-sized vesicles for inhalation | MSCs-derived exosomes | Phase II (NCT04445246) | ||
Inhalation solution | PUL-042 | Phase II (NCT04312997, NCT04313023) | ||